Physician profile
Van E Lomis
NPI 1689765059
$6,200.97
in general payments reported to CMS, 2019-2025
31 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $534 · 2021: $774 · 2022: $868 · 2023: $1,095 · 2024: $1,299 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,434 · Education: $77.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,434.14 |
| Education | $77.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,013.81 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $898.74 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $692.73 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $517.58 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Abbvie INC. | $427.73 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $396.49 | 2019-2025 | Jardiance, Synjardy |
| Dexcom, INC. | $296.43 | 2024-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| E.R. Squibb & Sons, L.L.C. | $263.18 | 2019-2024 | Camzyos |
| Amarin Pharma, INC. | $258.86 | 2020-2022 | |
| Glaxosmithkline, LLC. | $244.03 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $180.66 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Astellas Pharma US INC | $154.89 | 2023-2025 | Veozah |
| Pfizer INC. | $145.34 | 2021-2025 | |
| Exact Sciences Corporation | $144.31 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $83.75 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $77.45 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $55.63 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $47.47 | 2019-2021 | |
| Horizon Therapeutics Plc | $37.03 | 2021-2022 | |
| Allergan, INC. | $33.24 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.09 | 2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $32.31 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company Ltd. | $30.75 | 2022 | |
| Eisai INC. | $29.17 | 2020-2021 | |
| Esperion Therapeutics, INC. | $18.48 | 2025 | Nexletol |
| Nevro Corp. | $16.07 | 2024 | Senza |
| Almatica Pharma LLC | $15.95 | 2023 | Loreev Xr |
| Amgen INC. | $15.20 | 2021 | |
| Genentech USA, INC. | $14.23 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.35 | 2024 | Zoryve |
| Avanir Pharmaceuticals, INC. | $13.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Lomis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.